Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017
Added 1 month ago Drug news
FDA approves Mvasi (bevacizumab-awwb) biosimilar for non-small cell lung cancer, for metastatic colorectal cancer, glioblastoma, metastatic renal cell carcinoma and carcinoma of the cervix.- Amgen and Allergan.
Amgen and Allergan announced that the FDA has approved Mvasi (bevacizumab-awwb) for all eligible indications of the reference product, Avastin...
Added 6 months ago Drug news
FDA grants 510(k) clearance for the CINtec Histology test to determine which women should receive treatment for cervical pre-cancer. Roche
Roche has announced it has received 510(k) clearance from the FDA for the CINtec Histology test. This test is the...
Added 8 months ago Drug news
First patient dosed in Phase III AIM2CERV trial evaluating axalimogene filolisbac as an adjuvant therapy for high-risk, locally advanced, carcinoma of the cervix. -Advaxis
Advaxis, Inc. announced that the first patient has been enrolled and dosed in its AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Cervical cancer is the second most commonly diagnosed cancer and the third leading cause of cancer death among females in less developed countries. These updated guidelines focus on the management...
Added 5 years ago
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study.
Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning.
Added 1 month ago
Introduction: Cervical cancer is still a major cause of morbidity and mortality in women. Early stages and locally advanced cervical...
Added 1 year ago
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
BACKGROUND: Despite preventive vaccines for oncogenic human papillomaviruses (HPVs), cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative...
Added 2 years ago
Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more
Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.